Personalis Expands Genomics Portfolio Across Disease Areas With Launch of Pharma Research Solns for Use in Early Drug Discovery, Preclinical Studies
A third stock that I believe will do well in 2020 is a sleeper name that has done very poorly since its IPO this past June. Currently the company's biggest client is the Veterans Administration. Personalis recently announced a $38.1 million order from the VA's Million Veteran Program.
Personalis Announces Renewed Clinical Laboratory Accreditation from College of American Pathologists
Indivumed, Personalis Partner to Enhance Genomic Sequencing Capabilities.
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (PSNL), a leader in advanced genomics for cancer, today announced a collaboration to leverage Personalis’ ImmunoID NeXT Platform in Advaxis’ ongoing Phase 1/2 ADXS-503 (HOT Lung) program evaluating ADXS-503 alone and in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC). The ADXS-503 construct targets 11 public or shared, hotspot neoantigens in KRAS, EGFR and TP53 as well as 11 proprietary tumor-associated antigen targets.
Personalis to Participate at the 19th Annual Needham Virtual Healthcare Conference
Scott+Scott Attorneys at Law LLP Announces Investigation into Personalis, Inc. (PSNL)
Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Personalis earnings conference call. Joining me on today's call are John West, president and chief executive officer; and Aaron Tachibana, chief financial officer.
Personalis to Announce Fourth Quarter and Full Year 2019 Financial Results on March 25, 2020
NEW YORK, NY / ACCESSWIRE / March 25, 2020 / Personalis Inc (NASDAQ:PSNL) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 25, 2020 at 5:00 PM Eastern ...
Personalis to Participate at Upcoming Investor Conferences
Given broader market weakness, this is a good time to take a look at these names and develop strategies.
PHILADELPHIA, May 28, 2020 -- Kehoe Law Firm, P.C. is investigating Personalis, Inc. (“Personalis” or the “Company”) (NASDAQ: PSNL) for potential federal securities law.
Personalis Reports Fourth Quarter and Full Year 2019 Financial Results
One third of this year's Bay Area companies that went public in the past 12 months entered trading on the day after Christmas below their original offering prices.
Personalis to Announce First Quarter 2020 Financial Results on May 7, 2020
Personalis Reports First Quarter 2020 Financial Results
Personalis, Inc. Appoints Industry Veteran Stephen Moore as General Counsel